脑钠素N端前体肽在原发性高血压发病中的意义

目的:观察脑钠素N端前体肽Nt-ProBNP1～76水平在原发性高血压患者体内的改变及与血压的关系。方法:选择2003-06/2003-10解放军总医院收治的原发性高血压患者54例,其中高血压1级者31例,高血压2级者23例(血压划分标准按照美国JNC-6标准)。采用放射免疫分析方法检测血浆Nt-ProBNP1～76、心钠素以及内皮素的水平,以同期健康体检的31例正常人为对照组。并应用直线相关分析对两组被试者血压与Nt-ProBNP1～76之间的关系进行了分析。结果:按意向处理分析,54例被试者全部进入结果分析。①Nt-proBNP1～76浓度:高血压组显著高于对照组[(289.67±52.25),(178.17±42.56)ng/L,P<0.01]。②血浆心钠素:高血压组显著高于对照组[(123.46±8.57),(76.28±7.62)ng/L,P<0.01],2级患者高于1级患者(P<0.05)。③内皮素:高血压组显著高于对照组[(167.23±10.54),(132.29±11.37)ng/L,P<0.01],2级患者高于1级患者(P<0.05)。④血浆Nt-proBNP1～76水平与血压相关性:在对照组,收缩压和舒张压均与Nt-proBNP1～76间呈正相关(r=0.84,0.81;P=0.046,0.035);在高血压组,收缩压与Nt-proBNP1～76间呈正相关(r=0.59,P=0.027)。结论:血浆ProBNP1～76水平在原发性高血压的发生发展过程中可能起者重要的作用。测定血浆ProBNP1～76水平对于监测高血压患者是否发生左心室肥厚有其重要临床意义,脑钠素前体肽的测定可望成为判断高血压病预后的指标。     

N-端脑钠肽前体测定在高血压疾病中的应用研究

目的 探讨血清N端脑钠肽前体(NT-proBNP)在高血压疾病的应用研究。方法 选择152例高血压患者纳入研究,根据高血压病情发展分为高血压1级(30例),高血压2级(36例)和高血压3级(86例)。86例高血压3级患者根据有无并发糖尿病又分为单纯高血压组(40例)和高血压并发糖尿病组(46例),分别比较不同分级组的血清NT-proBNP水平变化。结果 高血压1级患者、2级患者和3级患者血清中NT-proBNP水平分别为68±44,122±31和834±309 pg/ml。随着病情发展其血清水平逐渐升高(t=2.455,3.561,P<0.01),高血压3级患者中高血压并发糖尿病组和单纯高血压组血清中NT-proBNP分别为1 178±664 pg/ml和599±411 pg/ml(t=3.785,P<0.01)。结论 NT-proBNP水平能客观反映高血压患者的病情程度,对临床治疗和病情监测有一定的指导意义。     

急性心肌梗死患者血浆N端脑钠肽前体测定及其意义

脑利钠肽（BNP）是一种心脏神经激素，当心室壁张力增加时，心室肌细胞受到牵拉刺激，就会以激素原的形式爆发式合成，最后裂解为由32个氨基酸组成的BNP分子与76个氨基酸组成的N端脑钠肽前体（NT-proBNP）片段，并将2者同时释放人血循环，发挥生物活性。在血浆中NT—proBNP分子与BNP分子以1：1的比例存在于血循环中，[第一段]     

急性心肌梗死患者血浆N端脑钠肽前体测定及其意义

脑利钠肽(BNP)是一种心脏神经激素,当心室壁张力增加时,心室肌细胞受到牵拉刺激,就会以激素原的形式爆发式合成,最后裂解为由32个氨基酸组成的BNP分子与76个氨基酸组成的N端脑钠肽前体(NT-proBNP)片段,并将2者同时释放入血循环,发挥生物活性[1].……     

高血压患者血清胱抑素C和N端脑钠肽前体水平研究

目的探讨高血压患者血清胱抑素C(CysC)和N端脑钠肽前体(NT-proBNP)水平的变化。方法选取89例高血压患者并分为5个亚组:A组(20例),单纯性高血压组;B组(18例),高血压合并左心肥厚组;C组(15例),高血压合并心力衰竭组;D组(17例),高血压合并早期肾功能损害组;E组(19例),高血压合并冠心病组。并选取20例健康体检者作为对照组,测定各组血清CysC和NT-proBNP水平。结果 B、C、D组的CysC水平高于对照组,E组CysC水平低于对照组,差异均有统计学意义(P<0.05)。D组的NT-proBNP水平高于对照组(P<0.05),B、C、E组NT-proBNP水平显著高于对照组(P<0.01),差异均有统计学意义。结论测定高血压患者血清CysC和NT-proBNP水平可以了解病情的发展及合并疾病发生情况,为临床治疗提供依据。     

N端前体脑钠肽检测在脓毒症中的应用研究

目的：检测N端前体脑钠肽（NT-proBNP）在不同程度脓毒症中的水平及其在临床预后中的应用。方法：选择38例脓毒症和25例一般感染患者,采用罗氏心脏标志物分析仪,分别检测血NT-proBNP、肌钙蛋白（cT nT）、C反应蛋白（CRP）的水平,同时选择18例健康人作为正常对照组检测上述指标。结果：血NT-proBNP水平在脓毒症组明显高于一般感染组及正常对照组,三组比较差异有统计学意义（P〈0.05）;NT-proBNP水平在一般感染组与正常对照组之间比较,差异无统计学意义（P〉0.05）。在不同的脓毒症组,血NT-proBNP不同程度地相应升高,其中血NT-proBNP水平在脓毒性休克组最高,三组间差异有统计学意义（P〈0.05）;血NT-proBNP水平与血cT nT、血CRP水平在不同脓毒症组间呈正相关,差异有统计学意义（P〈0.05）。结论：NT-proBNP有望成为一个预警脓毒症发生、预测脓毒症病情程度及临床预后的实验室指标。     

N端脑钠肽前体检测在临床疾病诊断中的研究

目的 探讨血清N端脑钠肽前体在心脏功能衰竭、脑梗死及肾脏功能衰竭疾病的诊断以及治疗监测中的研究.方法 选择健康体检者30例作为正常对照组,同时选取经临床确诊的心功能衰竭患者101例、脑梗死患者95例及肾脏功能衰竭患者66例;采用罗氏全自动电化学发光免疫分析系统检测受检者血清N端脑钠肽前体浓度.结果 正常对照组、肾功能衰竭组、心功能衰竭组及脑梗死组血清N端脑钠肽前体的检测结果（（x）±s,pg/ml）分别为：55.41±25.63,15 110.08±22 951.45,5 082.35±9 546.15和1 960.06±2 653.07.正常对照组与临床三组间及临床三组之间结果经t检验分析,t值在-2.73-6.99之间,P均＜0.01,差异有统计学意义.结论 血清N端脑钠肽前体浓度水平不仅是评价和监测心功能状态的良好指标,同时对脑梗死及肾脏功能衰竭患者的诊断与治疗监测亦具有重要的临床意义.研究结果表明,即血清N端脑钠肽前体浓度水平在临床疾病的诊断中具有非常广泛的应用价值.     

急性冠脉综合征患者早期N端脑钠肽前体水平测定的意义

目的：研究急性冠脉综合征患者早期N端脑钠肽前体（NT-proBNP）浓度及其与急性冠脉综合征患者急性期心功能及其预后的关系。方法：对50例初发的急性冠脉综合征患者在起病24h内及病程的第4周分别采血，测定患者血清NT-proBNP1及NT-proBNP2；并在病程的第3～4周测定入选患者的左室舒张末径（LVDd）、左室射血分数（LVEF）；根据患者心脏功能状况（Killip分级）分为两组，A组，Ⅰ级，B组，Ⅱ～Ⅳ级，进行NT-proBNP浓度的比较。结果：急性冠脉综合征患者早期的NT-proBNP浓度高于对照组（P〈0．001），无明显心力衰竭的A组与对照组比较也得出类似的结果；有心力衰竭的B组患者与无明显心力衰竭的A组比较其血清NT-proBNP1、NT-proBNP2及血浆TnT1均较高（P〈0．05），EF则较低（P〈0．05）。死亡组与非死亡组的比较，死亡组患者有着较大的年龄和较高的NT-proBNP值（P〈0．001）。急性冠脉综合征患者早期的NT-proBNP浓度与其它的变量的相关性研究表明，NT-ProBNP浓度与年龄、Killip分级正相关，与EF值负相关。结论：急性冠脉综合征患者早期的NT-proBNP浓度与急性期心功能状况及预后密切相关，对急性冠脉综合征患者早期进行血清NT-proBNP浓度的测定具有重要的临床意义。     

N-末端脑钠肽前体在心血管疾病诊治中的应用价值

N-末端脑钠肽前体是近年来心血管疾病中研究的热点,被认为是心血管疾病诊断和预后的重要血清标志物,有助于冠心病患者的早期危险分层,早期识别高危人群,用于辅助诊断、指导治疗及判断预后。本文就NT-proBNP在常见的心血管疾病诊治中的应用现状做一综述。     

N端脑利钠肽前体对急性心肌梗死常规检查的可行性研究

目的 探讨N端脑利钠肽前体(NT-proBNP)检测在急性心肌梗死(AMI)患者诊疗中的临床价值及将其纳入AMI常规检查的可行性.方法 选取84例经确诊的AMI患者,按Killip法将其分为4个心功能级别,检测NT-proBNP水平,同时检测cTnT、CK-MB,并与30例健康对照者作比较,收集临床相关资料,分析各指标...     

Pediatric brain natriuretic peptide and N-terminal pro-brain natriuretic peptide reference intervals

BACKGROUND: Brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) have been shown to be useful biomarkers for the diagnosis of heart failure. Pediatric reference intervals for these analytes have been reported in part. Previous studies lack large numbers in each group, have not covered all age ranges and have not compared results for BNP with NT-proBNP in simultaneously drawn samples. METHODS: We measured BNP in whole blood using the Biosite Triage point-of-care method and plasma NT-proBNP using the Dade RxL Dimension. We assessed between and within-day precision of both methods and after removing outliers employed the Hoffmann approach to calculate pediatric reference intervals over the age range of 0-21 y. We also compared the 2 methods on simultaneously drawn samples. RESULTS: Reference intervals revealed approximately 20-fold higher 97.5th percentiles for neonates than for children >3 y of age. 97.5th percentiles decreased significantly over the first 3 years of life. As shown by others, the CVs for the automated Dade RxL platform were somewhat lower than those for the POCT method. BNP and NT-proBNP correlated well in simultaneously drawn samples (r=0.947). DISCUSSION: Reference intervals for BNP and NT-proBNP are far higher in neonates and infants than in children older than three years of age. The reasons for this are unknown but resemble the elevated CK-MBs and troponins also found in neonates, although the 97.5th percentiles for these latter 2 cardiac markers decrease more rapidly to values found in older children by 6 months of age.     

血清N末端B型钠尿肽原在不明原因呼吸困难病因分析中的临床意义

目的探讨血清N末端B型钠尿肽原(NT-proBNP)在不明原因呼吸困难病因分析的临床意义。方法针对急诊入院不明原因呼吸困难的患者,应用电化学发光法检测患者血清NT-proBNP的浓度;详细追问病史、体格检查,结合心电图、心脏彩超、胸片、肺功能测定等相关检查,进一步明确患者呼吸困难的原因。结果心源性呼吸困难患者血清NT-proBNP浓度在829.20~18700.50 pg/ml间,NT-proBNP呈偏态分布,中位数水平分别为4474.80 pg/ml,非心源性呼吸困难患者血清NT-proBNP浓度在10.20~389.50 pg/ml间,NT-pro BNP呈偏态分布,中位数水平分别为174.20 pg/ml,两组患者血清NT-proBNP浓度中位数比较差异有统计学意义(P值0.05)。结论血清NT-proBNP浓度在鉴别心源性或非心源性呼吸困难中有重要意义。     

Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction

Brain natriuretic peptide (BNP), NT-proBNP and NT-pro-atrial natriuretic peptide (NT-proANP) were measured in blood samples from 57 patients using immunoassays and immunoradiometric assays to evaluate the usefulness as diagnostic markers for the detection of heart failure. For the detection of impaired left ventricular ejection fraction (LVEF), receiver operating characteristic curves showed that BNP had the best diagnostic performance with an area under curve (AUC) of 0.75±0.06. However, NT-proBNP (AUC: 0.67±0.07) and NT-proANP (AUC: 0.69±0.08) showed no significant difference to BNP. In a further analysis for the detection of resting LVEF <40%, BNP again was the best marker with an AUC of 0.83±0.06. NT-proBNP showed only a slightly smaller AUC (0.79±0.07). The AUC for NT-proANP was significantly smaller (0.65±0.08) compared to BNP. Additionally, BNP and NT-proBNP correlated negatively with the resting LVEF (BNP: −0.472, p<0.001; NT-proBNP: −0.306, p=0.026), whereas NT-proANP showed no significant correlation. In summary, BNP was the best marker to detect patients with impaired LVEF compared to NT-proBNP and NT-proANP. However, NT-proBNP showed no significant differences to BNP and it is therefore a new promising alternative marker for the detection of left ventricular dysfunction.     

N-末端脑钠肽与心力衰竭的相关性

目的探讨血浆N-末端脑钠肽(NT-ProBNP)水平与心力衰竭程度的相关性。方法选择器质性心脏病心力衰竭患者443例(心力衰竭组)和同期住院的无器质性心脏病患者110例(对照组)作为研究对象,采用电化学发光全自动免疫分析仪测定两组患者血浆NT-ProBNP水平,评价NT-ProBNP水平与心力衰竭及心血管事件发生的关系。结果心力衰竭组NT-ProBNP水平显著高于对照组(P<0.05);且心力衰竭患者的NYHA心功能分级越高,NT-ProBNP水平越高(P<0.05),再发心血管事件发生率也越高。结论 NT-ProBNP在心力衰竭临床诊断、心功能分级及预后评估中具有重要的地位和价值,可作为监测心功能的良好指标。     

Plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in assessment of acute dyspnea.

We examined the analytical correlation between non-radioimmunometric plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) and B-type natriuretic peptide (BNP) and evaluated whether NT-proBNP or BNP was superior in the emergency diagnosis of heart failure and whether this was influenced by age, gender, body mass index (BMI) and renal function. Data were collected prospectively from patients admitted to the emergency department for acute dyspnea. Plasma BNP (Triage, Biosite) and NT-proBNP (Elecsys, Roche diagnostic(R)) were measured at admission in addition to other standard biological parameters and clinical variables. Reference diagnosis was adjudicated by two independent cardiologists using the European society of cardiology guidelines. We evaluated the influence of creatinine clearance, age, gender and BMI on plasma BNP and NT-proBNP levels. One hundred and sixty consecutive patients were included: 84 females and 76 males, mean age 80.1 + 13.5 (16-98). The analytical correlation between the automated electro-chemiluminescence immunoassay for NT-proBNP and the single use fluorescence immunoassay for BNP was satisfactory using the equation: NT-proBNP = 1.1 BNP + 0.57 and a correlation r = 0.93. This was established over a wide range of concentration (5-6400 pg/ml for BNP). Areas under receiver operating characteristic (ROC) curve for BNP and NT-proBNP as a diagnostic marker for heart failure were 0.82 and 0.84, respectively and a BNP level of 150 pg/ml has similar sensitivity and specificity that NT-proBNP level of 1000 pg/ml. The correlation was not influenced by age, gender and BMI of patients. Renal dysfunction did not affect significantly this correlation (r = 0.93). We conclude that NT-proBNP, as assayed in the present study, correlates closely with BNP. This correlation is only slightly modulated by creatinine clearance values. The NT-proBNP appears as accurate as BNP according to area under ROC curve. Used in conjunction with other clinical information, rapid measurement of BNP or NT-proBNP is useful in establishing or excluding the diagnosis of congestive heart failure in patients with acute dyspnea.